Ingaran Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-06-2024
- Paid Up Capital ₹ 0.10 M
as on 20-06-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.00 M
as on 20-06-2024
- Revenue %
(FY 2019)
- Profit 36.81%
(FY 2019)
- Ebitda 60.20%
(FY 2019)
- Net Worth -7.22%
(FY 2019)
- Total Assets -5.13%
(FY 2019)
About Ingaran Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sunitha Namala, Kalyan Namala, Purushottam Muppana, and One other member serve as directors at the Company.
- CIN/LLPIN
U01403TG2011PTC074400
- Company No.
074400
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ingaran Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalyan Namala  | Managing Director | 10-May-2011 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunitha Namala | Additional Director | 30-Mar-2024 | Current |
| Purushottam Muppana | Director | 10-May-2011 | Current |
| Suneetha Sekuri | Additional Director | 30-Mar-2024 | Current |
Financial Performance of Ingaran Biotech.
Ingaran Biotech Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 36.81% increase in profit. The company's net worth dipped by a decrease of 7.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ingaran Biotech?
In 2015, Ingaran Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Coastal Laboratories Private LimitedActive 14 years 3 monthsSunitha Namala and Kalyan Namala are mutual person
Kakinada Chit Funds Private LimitedActive 28 years 3 monthsKalyan Namala and Purushottam Muppana are mutual person
- Priyavision Communications Private LimitedActive 24 years 6 months
Purushottam Muppana is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andra Bank Creation Date: 10 Oct 2013 | ₹5.00 M | Satisfied |
How Many Employees Work at Ingaran Biotech?
Unlock and access historical data on people associated with Ingaran Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ingaran Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ingaran Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
